Significance of epithelial membrane antigen in the work‐up of problematic serous effusions

Abstract

Differentiation of reactive and/or atypical mesothelial cells from malignant epithelial cells in serous effusions remains a frequent diagnostic problem. Since epithelial membrane antigen (EMA) positive malignant cells in serous effusions have been reported in almost all adenocarcinomas and most malignant mesotheliomas, immunoreactivity for EMA is felt to be less useful than other antibodies in the workup of problematic serous effusions. However, immunostaining of reactive and/or atypical benign mesothelial cells for EMA has not been well studied, with only a few series reporting either weak or negative staining for EMA. This study was undertaken to evaluate how often reactive and/or atypical appearing mesothelial cells stain positively for EMA. One hundred eighty serous effusions (115 pleural, 55 peritoneal, and 10 pericardial) from 123 females and 57 males ages 20 to 89 yr were evaluated in which an antibody panel including EMA was performed on cell blocks (141 cases), cytospins (36 cases), or both (3 cases). Of the 100 cytologically positive cases, EMA immunoreactivity was present in 97/100 (97%) cases. One EMA negative case suspicious for a metastatic renal cell carcinoma was lost to follow-up and not included in the analysis. The remaining three negative cases consisted of malignancies not expected to have EMA positive cells (small cell carcinoma, neuroblastoma, and synovial sarcoma). Therefore, EMA was positive in virtually 100% of the remaining malignant cases. In the 78 cytologically negative cases, EMA positivity was present in 3/78 (3.8%) cases. Clinical follow-up of up to 14 mo in these three cases revealed no evidence of malignancy.(ABSTRACT TRUNCATED AT 250 WORDS)

An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions

“…The investigation of EMA, CEA (CD66abce), and cytokeratin expression has also been proposed for improving the cytodiagnosis of effusions (2,10,(35)(36)(37)(38). In malignant effusions from metastatic adenocarcinoma, EMA has been shown to be strongly positive, and Ber-EP4 and CD66abce also expected to be positive.…”

Mesothelial cell inclusions mimickingadenocarcinoma in cervical lymph nodes in association with chylous effusion

“…EMA immunopositivity is seen in only 3–4% of reactive mesothelial cells as compared to malignant mesothelioma. [89] However, the malignant mesothelial cells are characterized by strong membranous reactivity. [89] The present case showed weak cytoplasmic EMA positivity.…”

“…[89] However, the malignant mesothelial cells are characterized by strong membranous reactivity. [89] The present case showed weak cytoplasmic EMA positivity. We consider the cells as benign based on the above features and also a thorough clinical, radiological and biochemical evaluation was negative for any malignant disease.…”

E-cadherin expression is a sensitive and specific method for detection of carcinoma cells in fluid specimens

“…11 Even using this or other such panels, 12 some tumors are still not identified, resulting in test sensitivity in the 80 -85% range. 14 The unique potential advantages of E-cadherin over these panels are: 1) it may be used without other antigens (not part of a panel) with equal or better sensitivity, and 2) its unique expression patterns lead to high specificity. 14 The unique potential advantages of E-cadherin over these panels are: 1) it may be used without other antigens (not part of a panel) with equal or better sensitivity, and 2) its unique expression patterns lead to high specificity.…”